Covista (DVY) AI Stock Analysis

6 Followers

Covista

(Frankfurt:DVY)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Sustained Enrollment GrowthBroad-based enrollment growth across all three segments indicates continued demand for Covista’s education offerings and supports recurring revenue expansion. The 13-quarter growth streak, including record Walden enrollment, suggests improving scale and a durable platform for future operating leverage.

Negative Factors

Gross Margin CompressionThe sharp decline in gross margin signals cost pressure or an unfavorable mix shift that could limit earnings conversion even while revenue grows. If it persists, lower gross profitability may constrain reinvestment capacity and make future operating-margin expansion more difficult.

Covista (DVY) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 4.07B
Dividend Yield: ―
Average Volume (3M): 13
Price to Earnings (P/E): 15.5
Beta (1Y): 0.38
Revenue Growth: 3.80%
EPS Growth: 11.16%
Country: Germany
Employees: 4,754
Sector: Consumer Defensive
Sector Strength: 62
Industry: Education & Training Services

Covista Business Overview & Revenue Model

Company Description

Covista Inc. is an enterprise dedicated to providing higher education. The company organizes its operations into three primary divisions: Chamberlain, Walden, and Medical and Veterinary. The Chamberlain segment delivers various degree and non-degree...

Covista Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q1-2027)|% Change Since:-4.73%|Next Earnings Date:Feb 01, 2027

Earnings Call SentimentPositive

The call was strongly positive. Covista reported double-digit revenue, EBITDA, net income, and EPS growth; continued company-wide enrollment gains; record Walden enrollment; strong medical and veterinary profitability; robust free cash flow; and raised fiscal 2027 revenue and EPS guidance. The main challenges were slower-than-expected Chamberlain enrollment, campus startup investments, medical-school financing hesitancy, quarterly calendar effects, a higher tax rate, and the announced CFO transition.

Positive Updates

Strong First-Quarter Company Performance

Revenue increased 10.7% to $511.5 million, adjusted EBITDA increased 17.1% to $131.2 million, adjusted net income increased 16.8% to $75.8 million, and adjusted EPS increased 25.1% to $2.19. Adjusted EBITDA margin expanded 1.4 percentage points to 25.6%.

Negative Updates

Chamberlain Enrollment Was Below Expectations

Management said Chamberlain's 1.3% total enrollment growth was incrementally below expectations. Fewer continuing students returned in September than forecast, and postlicensure RN-to-BSN enrollment remained soft.

Company Guidance

For fiscal 27, Covista now expects revenue in the range of $2.06 billion to $2.095 billion or approximately 5.5% to 7% growth year over year, up from its prior range of $2.05 billion to $2.09 billion, with a midpoint increase of $7.5 million; adjusted earnings per share is expected in the range of $9.00 to $9.20 or approximately 9% to 11.5% growth year over year, up from $8.90 to $9.15, with a midpoint increase of $0.07. The company is taking a prudent view of the remaining 3 quarters, expects 0 to 0.5 percentage points of EBITDA margin expansion for the full year, or up to 50 basis points of improvement, expects capital expenditures to be above fiscal 26 levels with higher spending weighted towards the first half of the year, and expects a higher effective tax rate in fiscal 27 than in fiscal 26. Walden will have 1 less week in the second quarter and 1 additional week in the third quarter compared with fiscal 2026, shifting $18 million of revenue and adjusted EBITDA from the third quarter into the second quarter last year, with no net impact on the full year.

Covista Risk Analysis

Covista disclosed 46 risk factors in its most recent earnings report. Covista reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

2 New Risks

1.Increased use of artificial intelligence ("AI") in our programs and processes or by others may subject us to increased business, compliance, and legal risk.Q2, 2026

2.Recent changes to federal student loan programs that reduce annual, aggregate, and lifetime borrowing limits and limit federal student aid for part-time students may limit students' ability to finance their education, which may in turn materially and adversely affect our results of operations.Q2, 2026

Covista Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

DE:DVY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRDO	79Outperform	$1.86B	10.63	17.70%	2.09%	11.68%	18.98%
LRN	74Outperform	$3.18B	9.50	20.59%	―	2.48%	7.90%
LOPE	73Outperform	$3.90B	17.88	31.24%	―	6.97%	0.18%
STRA	72Outperform	$1.61B	12.04	8.19%	3.24%	3.53%	23.97%
APEI	70Outperform	$761.16M	16.86	15.30%	―	3.64%	129.52%
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%

* Consumer Defensive Sector Average

Performance Comparison

DE:DVY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:DVY	Covista Inc.	110.70	31.70	40.13%
APEI	American Public Education, Inc.	42.33	10.91	34.72%
PRDO	Perdoceo Education Corporation	29.66	-0.15	-0.50%
LOPE	Grand Canyon Education	148.73	-29.55	-16.58%
LRN	Stride, Inc.	75.05	3.15	4.38%
STRA	Strategic Education	74.04	1.46	2.01%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Covista AI Stock Analysis